P. Fuller

Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Karin M. Otte, G. Morriello, B. Pio, 2021, RSC medicinal chemistry.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

Arthur Christopoulos, Christopher Southan, Stephen PH Alexander, 2017, British journal of pharmacology.

Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors.

Matthew L. Maddess, Y. Liu, X. Fradera, 2022, ACS medicinal chemistry letters.

Identification of Kinases Responsible for p53-Dependent Autophagy

S. Shumway, J. MacKeigan, E. Spooner, 2019, iScience.

A Potent and Selective ULK1 Inhibitor Suppresses Autophagy and Sensitizes Cancer Cells to Nutrient Stress

Jeffrey P. MacKeigan, S. Shumway, J. MacKeigan, 2018, iScience.

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.

Michael J. Ardolino, Karin M. Otte, M. Kennedy, 2021, Journal of medicinal chemistry.

The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.

Duan Liu, J. Klappenbach, X. Fradera, 2017, Journal of medicinal chemistry.

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease.

Theodore A. Martinot, Michael J. Ardolino, Matthew L. Maddess, 2022, Journal of medicinal chemistry.

Strategy for Extending Half-life in Drug Design and Its Significance.

M. Altman, B. Lahue, Scott A. Johnson, 2018, ACS medicinal chemistry letters.